TY - JOUR
T1 - The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment
AU - Ronco, Guglielmo
AU - Brezzi, Silvia
AU - Carozzi, Francesca
AU - Dalla Palma, Paolo
AU - Giorgi-Rossi, Paolo
AU - Minucci, Daria
AU - Naldoni, Carlo
AU - Segnan, Nereo
AU - Zappa, Marco
AU - Zorzi, Manuel
AU - Cuzick, Jack
PY - 2007/10
Y1 - 2007/10
N2 - Objectives.: To study the impact of different cervical cancer screening strategies including HPV testing. Methods.: A randomised controlled trial with a conventional arm (conventional cytology) and an experimental arm following two phases (first HPV testing + conventional cytology, second HPV testing alone). In phase one, different protocols were applied to different age groups (25-34 and 35-60). Published data on test accuracy during the phase one of recruitment are summarised. Results.: 45,307 women were recruited in phase one (about 95,000 overall). In the age group 35-60, HPV testing (by Hybrid Capture 2) alone at 2 RLU cut-off increased sensitivity vs. conventional cytology (relative sensitivity 1.41; 95% CI: 0.98-1.02) with a small loss in Positive Predictive Value (PPV; relative PPV 0.75; 95% CI: 0.45-1.25). Adding liquid-based cytology as screening test and referring to colposcopy women positive to either only marginally increased sensitivity but strongly reduced PPV. In the age group 25-34, similar results (relative sensitivity vs. conventional cytology 1.58; 95% CI: 1.032.44; relative PPV 0.78; 95% CI: 0.72-1.16) were obtained, despite 14% of women were HPV positive, with a strategy based on HPV alone as screening test, triaging HPV positive women by cytology, directly referring those ASCUS+ to colposcopy and repeating both tests after 1 year in those with normal cytology. Conclusions.: HPV testing, if used as screening test, should be applied alone, with cytology triage essential in younger women but preferable at all ages. Follow-up data will allow analysis of the safety of prolonging screening intervals and the relative persistence of lesions detected with different methods.
AB - Objectives.: To study the impact of different cervical cancer screening strategies including HPV testing. Methods.: A randomised controlled trial with a conventional arm (conventional cytology) and an experimental arm following two phases (first HPV testing + conventional cytology, second HPV testing alone). In phase one, different protocols were applied to different age groups (25-34 and 35-60). Published data on test accuracy during the phase one of recruitment are summarised. Results.: 45,307 women were recruited in phase one (about 95,000 overall). In the age group 35-60, HPV testing (by Hybrid Capture 2) alone at 2 RLU cut-off increased sensitivity vs. conventional cytology (relative sensitivity 1.41; 95% CI: 0.98-1.02) with a small loss in Positive Predictive Value (PPV; relative PPV 0.75; 95% CI: 0.45-1.25). Adding liquid-based cytology as screening test and referring to colposcopy women positive to either only marginally increased sensitivity but strongly reduced PPV. In the age group 25-34, similar results (relative sensitivity vs. conventional cytology 1.58; 95% CI: 1.032.44; relative PPV 0.78; 95% CI: 0.72-1.16) were obtained, despite 14% of women were HPV positive, with a strategy based on HPV alone as screening test, triaging HPV positive women by cytology, directly referring those ASCUS+ to colposcopy and repeating both tests after 1 year in those with normal cytology. Conclusions.: HPV testing, if used as screening test, should be applied alone, with cytology triage essential in younger women but preferable at all ages. Follow-up data will allow analysis of the safety of prolonging screening intervals and the relative persistence of lesions detected with different methods.
KW - Cervical cancer
KW - Cytology
KW - HPV
KW - RCT
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=34748818225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34748818225&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2007.07.021
DO - 10.1016/j.ygyno.2007.07.021
M3 - Article
C2 - 17822751
AN - SCOPUS:34748818225
SN - 0090-8258
VL - 107
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1 SUPPL.
ER -